-

Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.
Lifestyle Content
Technology
-
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
-
Affiliate of Jefferson Energy Companies Agrees to Acquire Crude Oil Logistics Assets from USD Group
-
Transaction in Own Shares
-
Comstock to Participate in the Lytham Partners Fall 2026 Investor Conference
-
Flyte Named Official Air Travel Partner of the 34th Annual Hamptons International Film Festival
Entertainment
-
Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
-
ShowBride Announces Winter 2027 Bridal Expo in Chesapeake, Virginia
-
Dmitry Druzhinsky Highlights Community-Based Approach to Long-Term Athlete Development at MatchPoint NYC
-
Nilla Steps Up as Presenting Sponsor of the 2026 National Banana Pudding Festival
-
Six Books. One. Paradise. An Entire Universe
Health
-
The AI career premium: How AI skills are accelerating career paths
-
RevOps job postings are outpacing hires so fast that one company is running the same search on two continents
-
How to explain being a futures trader to your friends and family
-
The life expectancy gap is putting a new focus on long-term financial planning
-
Banks made $3 billion from overdraft fees in just 6 months: Here’s how to avoid paying them










